Form 4: Humana Director David T. Feinberg Increases Equity Stake Through Stock Unit Acquisitions

Humana Inc. Director David T. Feinberg reported an increase in his beneficial ownership of company stock through the acquisition of restricted stock units as part of his compensation and dividend reinvestment.

Summary

• David T. Feinberg, a Director of Humana Inc., reported changes in his beneficial ownership of Humana common stock and restricted stock units (RSUs) in a recent SEC Form 4 filing.
• Following the reported transactions, Mr. Feinberg directly owns 441 shares of Humana Common Stock.
• He beneficially owns 1,593 restricted stock units (RSUs) derived from annual director fees, which are deferred until his resignation and are convertible to common stock on a 1-for-1 basis; this total includes 783 RSUs from the company's 2019 Amended & Restated Plan.
• On June 30, 2025, Mr. Feinberg acquired an additional 76 restricted stock units at a price of $242.815 per unit, resulting from the conversion of a director's cash fee.
• An additional 17 restricted stock units were acquired through the reinvestment of dividend payments on vested and deferred stock units, also convertible to common stock on a 1-for-1 basis.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of director compensation in the form of restricted stock units, which aligns the director's interests with shareholders. It does not contain any negative or unexpected information.

Positives

• Director David T. Feinberg is increasing his beneficial ownership in Humana Inc. through the acquisition of restricted stock units, which aligns his interests with those of shareholders.
• The acquisition of 76 restricted stock units at $242.815 per unit demonstrates a commitment to long-term equity participation in the company.
• Reinvestment of dividend payments into an additional 17 restricted stock units further increases the director's stake and commitment.

Future Outlook

The document does not contain any forward-looking statements or guidance beyond the deferred payment of stock units upon the director's resignation.

Industry Context

The reported transactions reflect standard corporate governance practices where directors receive a portion of their compensation in equity, such as restricted stock units, to align their interests with long-term shareholder value. This is a common practice across publicly traded companies, particularly in the healthcare and insurance sectors like Humana.

Comparison to Industry Standards

• The practice of compensating directors with restricted stock units (RSUs) and allowing for deferral or reinvestment of dividends into additional units is a common and accepted industry standard for aligning director incentives with shareholder interests.
• Many large healthcare companies, such as UnitedHealth Group (UNH) or CVS Health (CVS) (which owns Aetna), utilize similar equity-based compensation structures for their non-employee directors.
• The specific value of the RSU acquisition ($242.815 per unit) is a market-based price at the time of the transaction, consistent with fair valuation practices.

Related Party Transactions

• The acquisition of restricted stock units by a director as part of their compensation constitutes a related party transaction, which is disclosed as per SEC regulations.

Stakeholder Impact

• Shareholders: The director's increased beneficial ownership through stock units aligns his financial interests with the long-term performance of Humana Inc., potentially benefiting shareholders.

Next Steps

• The restricted stock units acquired from annual director fees and cash fee conversions will be payable in Humana Inc. common stock on a 1-for-1 basis upon the reporting person's resignation of services as a director.

Key Dates

Keywords

Humana Inc., HUM, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, RSU, Equity Compensation, David T. Feinberg, Beneficial Ownership